Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.

Inclusion Criteria: * Cytological or histologically confirmation of pancreatic cancer. * WHO performance status of 0 or 1 * ASA classification I or II * Tumor considered locally advanced after diagnostic work-up including CT-imaging and diagnostic laparoscopy. * No evidence of metastatic disease * Largest tumor diameter \< 7 cm x 7 cm x 7 cm * Normal renal function (Creatinine ≥ 30 ml/min). * Normal liver tests (bilirubin \< 1.5 times normal; ALAT/ASAT \< 5 times normal) * Normal bone marrow function (WBC \> 3.0 x 10e9/L, platelets \> 100 x 10e9/L and hemoglobin \> 5.6 mmol/l) * Age \> 18 years and \< 75 years * Written informed consent Exclusion Criteria: * Prior radiotherapy, chemotherapy or resection (bypass surgery allowed). * Lymph node metastases from primary tumor outside the field of radiation. * Second primary malignancy except in situ carcinoma of the cervix, adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years previously without evidence of recurrence. * Pregnancy, breast feeding. * Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.